Abstract

Biography

Dr Delphine Larrieu has been a Wellcome Trust Sir Henry Dale fellow and a Group Leader at the University of Cambridge since 2017. She initially set up her lab at the CIMR where she stayed for 5 years, and she was then appointed Assistant Professor in the Department of Pharmacology, where she relocated in October 2022.

After working on tumour suppressor genes during her PhD at the University Grenoble Alpes (France), she developed a strong interest in the mechanisms linking nuclear envelope dysfunction with ageing and premature ageing syndromes (progerias) during her postdoctoral training in Steve Jackson’s lab at the Gurdon Institute – Cambridge.

Her work has focused on the identification of new markers and modulators of nuclear envelope integrity, to unravel the mechanisms underlying nuclear envelope dysfunction, improve our understanding of premature and physiological ageing and contribute to the development of novel therapies. She has developed pioneering approaches based on the principle of synthetic rescue and relying on cutting-edge genetic screening approaches, and identified novel, unexpected targets and cellular pathways that can reverse several age-related nuclear envelope phenotypes. Her current efforts are focused on characterising and expanding the number of targets that can be exploited therapeutically to extend health and lifespan in progeria syndromes as well as in ageing.

Dr Larrieu is a co-founder of Adrestia Therapeutics – recently acquired by Insmed – a synthetic rescue company whose aim of restoring cellular balance in genetic diseases was directly inspired by her work.

Zoom link: https://zoom.us/j/94068850972?pwd=YmJoRTQ2NUZDRFNHWXd2R0FDc0hUUT09

Meeting ID: 940 6885 0972

Passcode: uY27KQv8cu